Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Amit Mahipal
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07226063CT.gov Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer | — | Not Yet Recruiting | — | — | — |
NCT07175441CT.gov Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07511504CT.gov Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07489976CT.gov IIT2025-03-YANG-LIFT-HCC | — | Recruiting | — | — | — |
NCT07166406CT.gov Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | — | Recruiting | — | — | — |
NCT07122089CT.gov Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis | — | Recruiting | — | — | — |
NCT07174570CT.gov Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer | — | Recruiting | — | — | — |
NCT06904170CT.gov Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06608940CT.gov BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT06880523CT.gov STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
Show 62 more trialsShow fewer
NCT06994299CT.gov A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT07012798CT.gov FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT07081633CT.gov Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT06999707CT.gov Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | — | Recruiting | — | — | — |
NCT06999694CT.gov Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC | — | Recruiting | — | — | — |
NCT06921785CT.gov Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06911255CT.gov Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06710223CT.gov Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab | — | Recruiting | — | — | — |
NCT06698250CT.gov Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) | — | Recruiting | — | — | — |
NCT06526104CT.gov Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis | — | Recruiting | — | — | — |
NCT05733598CT.gov Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | — | Recruiting | — | — | — |
NCT06470256CT.gov Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06045975CT.gov Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure | — | Active Not Recruiting | — | — | — |
NCT06040099CT.gov A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | — | Active Not Recruiting | — | — | — |
NCT06109272CT.gov A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT06117891CT.gov An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT05063565CT.gov TheraSphere With Durvalumab and Tremelimumab for HCC | — | Active Not Recruiting | — | — | — |
NCT05440864CT.gov Durvalumab and Tremelimumab in Resectable HCC | — | Recruiting | — | — | — |
NCT06111326CT.gov BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05451043CT.gov Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | — | Recruiting | — | — | — |
NCT05194293CT.gov Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT05883644CT.gov Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) | — | Active Not Recruiting | — | — | — |
NCT05864755CT.gov HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05701488CT.gov SIRT With Tremelimumab and Durvalumab for Resectable HCC | — | Recruiting | — | — | — |
NCT05844046CT.gov Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients | — | Recruiting | — | — | — |
NCT05312216CT.gov Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05557838CT.gov Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma | — | Recruiting | — | — | — |
NCT05809869CT.gov Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06218511CT.gov A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1) | — | Active Not Recruiting | — | — | — |
NCT04945720CT.gov Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT05301842CT.gov Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC | — | Active Not Recruiting | — | — | — |
NCT05155189CT.gov A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04430452CT.gov Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05027425CT.gov Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant | — | Terminated | — | — | — |
NCT04605731CT.gov Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT04517227CT.gov The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | — | Unknown | — | — | — |
NCT03937830CT.gov Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04522544CT.gov Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC | — | Recruiting | — | — | — |
NCT04988945CT.gov TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04294498CT.gov Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection | — | Active Not Recruiting | — | — | — |
NCT04913480CT.gov SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04443322CT.gov Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) | — | Unknown | — | — | — |
NCT04124991CT.gov Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC | — | Completed | — | — | — |
NCT03983954CT.gov Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | — | Active Not Recruiting | — | — | — |
NCT03638141CT.gov CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab | — | Completed | — | — | — |
NCT03970616CT.gov A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT03942328CT.gov Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | — | Recruiting | — | — | — |
NCT03899428CT.gov Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | — | Recruiting | — | — | — |
NCT03847428CT.gov Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment | — | Active Not Recruiting | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03778957CT.gov A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03539822CT.gov Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies | — | Recruiting | — | — | — |
NCT03611556CT.gov MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | — | Completed | — | — | — |
NCT03482102CT.gov Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | — | Active Not Recruiting | — | — | — |
NCT03257761CT.gov Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | — | Active Not Recruiting | — | — | — |
NCT03298451CT.gov Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT02898116CT.gov Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02821754CT.gov A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) | — | Completed | — | — | — |
NCT02572687CT.gov A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies | — | Completed | — | — | — |
NCT02519348CT.gov A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT01853618CT.gov Tremelimumab With Chemoembolization or Ablation for Liver Cancer | — | Completed | — | — | — |
NCT05345678CT.gov Himalaya Early Access Program | — | Approved For Marketing | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Durvalumab (this asset) | Amit Mahipal | P3 | B · 60 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Durvalumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Ovarian Carcinoma | — | P2 | BB · 70 |
| Primary Peritoneal Carcinoma | — | P2 | BB · 70 |
| Urothelial Carcinoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Durvalumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/durvalumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →